Trial Profile
Phase II study of rituximab in refractory or relapsed patients with multiple myeloma expressing CD20
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2013
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Zenyaku Kogyo
- 08 Jun 2009 New trial record.